Loading grant details…
1/2 Neonatal Platelet Transfusion Threshold Trial (NeoPlaTT)
| Funder | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE |
|---|---|
| Recipient Organization | Emory University |
| Country | United States |
| Start Date | May 15, 2024 |
| End Date | Apr 30, 2031 |
| Duration | 2,541 days |
| Number of Grantees | 2 |
| Roles | Principal Investigator; Co-Investigator |
| Data Source | NIH (US) |
| Grant ID | 10866100 |
Grant Description
Abstract Extremely preterm infants born at 23 to 26 weeks gestation have the highest incidence of thrombocytopenia and bleeding and the highest mortality among neonates admitted to the Neonatal Intensive Care Unit (NICU). Approximately 20% of extremely preterm infants develop a severe intracranial hemorrhage, almost always in
the first week of life, which is the highest risk period for bleeding. Platelet transfusions are frequently administered to extremely preterm neonates at higher platelet count thresholds than those used in older children and adults to decrease the risk of bleeding. Paradoxically, a recent multicenter randomized trial of
infants
All Grantees
Emory University
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
